Morpho-metabolic post-surgical patterns of non-infected prosthetic heart valves by [18F]FDG PET/CTA: "normality" is a possible diagnosis.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
01 01 2020
Historique:
received: 12 07 2019
accepted: 17 08 2019
pubmed: 21 9 2019
medline: 29 6 2021
entrez: 21 9 2019
Statut: ppublish

Résumé

To define characteristic PET/CTA patterns of FDG uptake and anatomic changes following prosthetic heart valves (PVs) implantation over time, to help not to misdiagnose post-operative inflammation and avoid false-positive cases. Prospective evaluation of 37 post-operative patients without suspected infection that underwent serial cardiac PET/CTA examinations at 1, 6, and 12 months after surgery, in which metabolic features (FDG uptake distribution pattern and intensity) and anatomic changes were evaluated. Standardized uptake values (SUVs) were obtained and a new measure, the valve uptake index (VUI), (SUVmax-SUVmean)/SUVmax, was tested to homogenize SUV results.In total, 111 PET/CTA scans were performed in 37 patients (19 aortic and 18 mitral valves). FDG uptake was visually detectable in 79.3% of patients and showed a diffuse, homogeneous distribution pattern in 93%. Quantitative analysis yielded a mean maximum standardized uptake value (SUVmax) of 4.46 ± 1.50 and VUI of 0.35 ± 0.10. There were no significant differences in FDG distribution or uptake values between 1, 6, or 12 months. No abnormal anatomic changes or endocarditis lesions were detected in any patient during follow-up. FDG uptake, often seen in recently implanted PVs, shows a characteristic pattern of post-operative inflammation and, in the absence of associated anatomic lesions, could be considered a normal finding. These features remain stable for at least 1 year after surgery, so questioning the recommended 3-month safety period. A new measure, the VUI, can be useful for evaluating the FDG distribution pattern.

Identifiants

pubmed: 31539031
pii: 5572144
doi: 10.1093/ehjci/jez222
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

24-33

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Albert Roque (A)

Department of Radiology, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
IDI (Institut de Diagnòstic per la Imatge), Spain.
Universitat Autònoma de Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, Barcelona, Spain.

María N Pizzi (MN)

Universitat Autònoma de Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Department of Cardiology, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

Nuria Fernández-Hidalgo (N)

Universitat Autònoma de Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

Eduard Permanyer (E)

Department of Cardiac Surgery, Quirónsalud Teknon Heart Institute, Carrer de Vilana 12, Barcelona, Spain.

Hug Cuellar-Calabria (H)

Department of Radiology, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
IDI (Institut de Diagnòstic per la Imatge), Spain.
Universitat Autònoma de Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, Barcelona, Spain.

Guillermo Romero-Farina (G)

Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, Barcelona, Spain.
Department of Cardiology, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

Remedios Ríos (R)

Universitat Autònoma de Barcelona, Spain.
Department of Cardiac Surgery, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

Benito Almirante (B)

Universitat Autònoma de Barcelona, Spain.
Department of Infectious Diseases, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.

Joan Castell-Conesa (J)

IDI (Institut de Diagnòstic per la Imatge), Spain.
Universitat Autònoma de Barcelona, Spain.
Department of Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Manuel Escobar (M)

Department of Radiology, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
IDI (Institut de Diagnòstic per la Imatge), Spain.

Ignacio Ferreira-González (I)

Universitat Autònoma de Barcelona, Spain.
Department of Cardiology, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, Spain.
CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Pilar Tornos (P)

Universitat Autònoma de Barcelona, Spain.
Department of Cardiology, Hospital Quirónsalud, Plaça d'Alfonso Comín 5, Barcelona, Spain.

Santiago Aguadé-Bruix (S)

Universitat Autònoma de Barcelona, Spain.
Department of Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH